Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004364905 | SCV004959497 | uncertain significance | Inborn genetic diseases | 2024-02-21 | criteria provided, single submitter | clinical testing | The c.1631A>G (p.N544S) alteration is located in exon 14 (coding exon 13) of the STT3A gene. This alteration results from an A to G substitution at nucleotide position 1631, causing the asparagine (N) at amino acid position 544 to be replaced by a serine (S). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. The in silico prediction for this alteration is inconclusive. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Undiagnosed Diseases Network, |
RCV003493389 | SCV004242209 | uncertain significance | Congenital disorder of glycosylation, type Iw, autosomal dominant | 2023-02-17 | no assertion criteria provided | clinical testing | CDG tandem mass spectrometry and found a unique profile consistent with that of CDG Type Iw. |